An FDA advisory panel narrowly supported allowing compounding pharmacies to manufacture the peptide epitalon, while recommending against compounding emideltide. The votes followed the panel’s earlier recommendations to permit pharmacies to make four other peptides, moving the proposal forward for additional unapproved peptide manufacturing. The panel’s decision brings health secretary Robert F. Kennedy Jr. closer to expanding access to certain unapproved compounds through compounding channels, while still drawing a line around the emideltide request. The peptide filings have been amplified amid public debate over compounding oversight and patient access.